Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.

@article{Knox2000BioactivationO5,
  title={Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.},
  author={Richard J. Knox and Terence C. Jenkins and Stephen M. Hobbs and Shaowei Chen and Roger G. Melton and Patrick J Burke},
  journal={Cancer research},
  year={2000},
  volume={60 15},
  pages={4179-86}
}
A novel prodrug activation system, endogenous in human tumor cells, is described. A latent enzyme-prodrug system is switched on by a simple synthetic, small molecule co-substrate. This ternary system is inactive if any one of the components is absent. CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is an antitumor prodrug that is activated in certain rat tumors via its 4-hydroxylamine derivative to a potent bifunctional alkylating agent. However, human tumor cells are resistant to CB 1954… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…